/

BVAXF

BioVaxys Technology Corp.Open

0.09000.00 0.00%USD

OTC Markets OTCPK · as of Oct 13, 16:00 ET · 15m delay

Open

0.0899

Prev close

0.0900

Day range

0.08990.0899

52-week range

0.01020.2200

Volume

10.00K0.42×

Mkt cap

3.66M

P/E ttm

—

Fwd P/E

—

EPS ttm

-0.1500

Div yield

0.00%

Earnings

—

From 52w high

−59.09%

Price Chart

Yahoo Finance · delayed

BVAXFOct 13, 2026O 0.0900H 0.0900L 0.0900C 0.09000.0000 (0.00%)

SMA 500.0895
SMA 2000.1074

1Y change −54.57% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

BVAXF BioVaxys Technology Corp. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −27.42%
1 month: −10.00%
3 months: −8.63%
6 months: +102.70%
Year to date: −46.84%
1 year: −54.57%

Valuation & ownership

Market cap: 3.66M
Enterprise value: 2.75M
P/E (ttm): —
Forward P/E: —
PEG ratio: —
Price / book: —
Price / sales (ttm): —
EV / EBITDA: —
EPS (ttm): -0.1500
EPS (forward): —
Beta (5y monthly): 1.60
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 40.65M
Float: 26.14M
Short % of float: —
Short ratio (days): —
Held by insiders: 8.23%
Held by institutions: 0.00%
Avg volume (3m): 23.90K
50-day average: 0.0893
200-day average: 0.1056
52-week change: −54.57%
S&P 500 52-week: +17.00%

Technicals (daily)

RSI (14): 48.5
vs 50-day SMA: +0.60%
vs 200-day SMA: −16.22%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 25.95%
Realised vol (20d, ann.): 279.4%
From 52-week high: −59.09%
From 52-week low: +782.35%

ANR

Analyst Consensus

No analyst coverage for this instrument.

Financial Snapshot

Full statements →trailing twelve months

Revenue (ttm): —
Revenue growth (yoy): —
Earnings growth (yoy): —
Gross margin: 0.00%
Operating margin: 0.00%
Profit margin: 0.00%

DES

About BioVaxys Technology Corp.

Yahoo Finance profile

BioVaxys Technology Corp., a clinical-stage biotechnology company, engages in developing viral and oncology vaccine platforms and immuno-diagnostics. The company offers DPX immune educating technology platform and HapTenix neoantigen tumor cell construct platform for treating cancers, infectious diseases, antigen desensitization, and other immune diseases. It also provides Maveropepimut-S (MVP-S), which has completed phase IIb clinical trial for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma and for platinum resistant ovarian cancer; MVP-S +1 Keytruda that is in IIb clinical trial to treat lung cancer, bladder cancer, liver cancer, DLBCL, and ovarian cancer subpopulations; BVX-0918, a haptenized tumor cell vaccine for ovarian cancer; and DPX SurMAGE, a formulation of the tumor-associated antigens survivin and MAGE A9 as a dual targeted immunotherapy. In addition, the company develops DPX-RSV that is in phase II clinical stage for Respiratory Syncytial Virus; DPX-Flu, which is in phase I clinical stage used to treat multiple strains of influenza; DPX-Neo, which is in phase I trial used for evaluating UConn Health's proprietary neoepitopes; DPX-E7 to evaluate changes in CD8+ T cells in peripheral blood and tumor tissue and evaluate the safety in HLA-A2positive patients; and DPX-rPA anthrax vaccine. Further, the company operates HapTenix Platform, a vaccine platform based on the established immunological concept that modifies surface proteins with haptens and T-Cell Antigen Discovery Program. It has agreement with AP Visionaries, Inc. to develop a proprietary DPX formulation to address the urgent need for a therapy to treat or alleviate the potentially life-threatening risk of certain food allergies triggered by exposure to peanut/tree nuts or eggs and Adiverna LLC to develop mRNA-based Rabies, Leptospirosis, Feline Infectious Peritonitis (FIV) and other mRNA-based vaccines for companion animal veterinary applications. BioVaxys Technology Corp. is headquartered in Etobicoke, Canada.

Sector: Healthcare
Industry: Biotechnology
Headquarters

SEAS

Seasonality · BVAXF

2018–2026 · monthly returns

Strongest month Apr +58.17%Weakest month Mar −19.02%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-18.8	-13.5	-50.5	-10.4	222.0	-24.7	-14.1	-36.5	19.6	7.8			−46.8%
2025	10.4	-18.2	-7.7	-37.9	38.4	-5.0	-22.9	-9.5	8.7	-7.5	-11.8	-5.0	−60.0%
2024	-14.0	98.5	-19.6	1.0	-0.4	-11.8	-6.8	-2.2	-3.3	21.1	-5.6	-15.9	+3.2%
2023	-13.7	-9.5	-29.3	-38.8	-40.0	28.9	-32.8	33.7	-27.6	-28.5	43.5	164.5	−53.8%
2022	-20.3	2.4	-13.7	-6.8	1.8	-24.9	36.4	-26.7	15.3	65.1	-19.3	-27.7	−44.2%
2021	78.6	67.0	-31.9	-23.8	-21.8	13.5	-10.3	-9.8	108.0	-13.5	-26.8	-27.4	+6.2%
2020	-6.4	23.2	-11.5	582.5	-24.7	0.0	0.0	0.0	0.0	90.2	-53.2	2.5	+378.7%
2019	67.1	0.0	-19.4	-69.1	78.0	32.1	-3.4	36.1	3.7	3.2	-44.7	-1.2	−24.7%
2018													—

BVAXF

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

BVAXF

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About BioVaxys Technology Corp.

Seasonality · BVAXF

Insider Activity · BVAXF

Congress Trades · BVAXF

Investors Holding BVAXF

Investors Holding BVAXF

Congress Trades · BVAXF

Insider Activity · BVAXF

Seasonality · BVAXF

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About BioVaxys Technology Corp.

Earnings & Dividends

News